ARKG is trading at $48.82, up 3.06%, amid broader healthcare strength, though available data do not identify a clear single driver.
- Healthcare stocks were flat to higher premarket; XLV advanced 1%.
- Rapport Therapeutics’ experimental drug met a Phase 2 trial’s primary endpoint, lifting its shares sharply premarket.
- Defensive positioning and expectations for potential midterm-related policy changes also support broader healthcare strength, which predates this session; ARKG’s largest holdings showed mixed moves.